Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Urology Reports
Published in: Current Urology Reports 1/2011

01-02-2011

Overactive Bladder and Outlet Obstruction in Men

Authors: Doreen E. Chung, Jaspreet S. Sandhu

Published in: Current Urology Reports | Issue 1/2011

Login to get access

Abstract

Lower urinary tract symptoms (LUTS), overactive bladder, (OAB), and benign prostatic hyperplasia (BPH) are very commonly experienced in men. The mainstay of pharmacotherapy for OAB is the antimuscarinic class of drugs. There has been reluctance to prescribe these agents to men with BPH due to the risk of precipitating urinary retention. Several trials have supported the efficacy and safety of antimuscarinics in treating men with LUTS, alone, or in combination with α-blocker therapy. The combination of 5-α-reductase inhibitors with antimuscarinic agents or surgery are other effective treatments for men with BPH and OAB.
Literature
1.
Abrams P, Cardozo L, Fall M, et al.: The standardization of terminology in lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Urology 2003, 61:37–49.CrossRefPubMed
2.
Jaffe WI, Te AE: Overactive bladder in the male patient: epidemiology, etiology, evaluation, and treatment. Curr Urol Rep 2005, 6:410–418.CrossRefPubMed
3.
Irwin DE, Milsom I, Hunskaar S, et al.: Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006, 50:1306–1314.CrossRefPubMed
4.
Kirby R, Lepor H: Evaluation and non-surgical management of benign prostatic hyperplasia, in Wein A, Kavoussi L, Novick A, et al., Urology, 9th ed. Philadelphia, Saunders Elsevier, 2007
5.
Abdel-Aziz KF, Lemack GE: Overactive bladder in the male patient: bladder, outlet, or both? Curr Urol Rep 2002, 3:445–451.CrossRefPubMed
6.
de Groat WC: A neurologic basis for the overactive bladder. Urology 1997, 50(6A Suppl):36–52PubMed
7.
Drake MJ, Mills IW, Gillespie JI: Model of peripheral autonomous modules and a myovesical plexus in normal and overactive bladder function. Lancet 2001, 358:401–403.CrossRefPubMed
8.
McGuire E: Neuromuscular dysfunction of the lower urinary tract in Walsh P, Gittes R, Perlmutter A, Stamey T: Campbell’s Urology. Philadelphia, W. B. Saunders, 1986.
9.
•• Kaplan SA, Roehrborn CG, Rovner ES, et al.: Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006, 296:2319–2328. This is the only placebo-controlled study published on combination therapy with α-blockers and antimuscarinic agents. CrossRefPubMed
10.
Kaplan SA, Walmsley K, Te AE: Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2008, 179:S82–85.CrossRefPubMed
11.
•• Abrams P, Kaplan S, De Koning Gans HJ, Millard R: Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006, 175:999–1004. This study is one of the few to investigate the effects of antimuscarinic therapy in patients with urodynamic BOO. CrossRefPubMed
12.
Lee JY, Kim HW, Lee SJ, et al.: Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU International 2004, 94:817–820.CrossRefPubMed
13.
Chapple CR, Roehrborn CG: A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006, 49:651–659.CrossRefPubMed
14.
Van Venrooij GE, Van Melick HH, Eckhardt MD, Boon TA: Correlations of urodynamic changes with changes in symptoms and well-being after transurethral resection of the prostate. J Urol 2002, 168:605–609.CrossRefPubMed
15.
Mehdizadeh JL, Leach GE: Role of invasive uodynamic testing in benign prostatic hyperplasia and male lower urinary tract symptoms. Urol Clin N Am 2009, 36:431–441.CrossRef
16.
Seki N, Kai N, Seguchi H, et al.: Predictives regarding outcome after transurethral resection for prostatic adenoma associated with detrusor underactivity. Urology 2006, 67:306–310.CrossRefPubMed
17.
Machino R, Kakizaki H, Ameda K, et al.: Detrusor instability with equivocal obstruction: a predictor of unfavorable symptomatic outcomes after transurethral prostatectomy. Neurourol Urodyn 2002, 21:444–449.CrossRefPubMed
18.
Coyne KS, Sexton CC, Irwin DE, et al.: The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in menand women: results from the EPIC study. BJU International 2008, 101:1388–1395.CrossRefPubMed
19.
Sexton CC, Coyne KS, Kopp ZS, et al.: The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int 2009, 103:12–23.CrossRefPubMed
20.
AUA Practice Guidelines Committee: AUA guideline on management of benign prostatic hyperplasia. Chapter 1: diagnosis and treatment recommendations. J Urol 2003, 170:530–547.CrossRef
21.
de la Rosette JJ, Alivizatos G, Madersbacher S, et al.: EAU Guidelines on benign prostatic hyperplasia (BPH). Eur Urol 2001, 40:256–263.CrossRefPubMed
22.
Hyman MJ, Groutz A, Blaivas JG: Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol 2001, 166:550–552.CrossRefPubMed
23.
Roehrborn CG: Focus on lower urinary tract symptoms: nomenclature, diagnosis, and treatment options. Rev Urol 2001, 3:139–145.PubMed
24.
Ball AJ, Smith PJ: Urodynamic factors in relation to outcome of prostatectomy. Urology 1986, 28:256–258.CrossRefPubMed
25.
van Venrooij GE, van Melick HH, Boon TA: Comparison of ourcomes of transurethral resection of the prostate in urodynamically obstructed versus selected urodynamically unobstructed or equivocal men. Urology 2003, 62:672–676.CrossRefPubMed
26.
Gerber GS, Kim JH, Contreras BA, et al.: An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin. Urology 1996, 47:840–844.CrossRefPubMed
27.
Kirby RS, Roehrborn CG, Boyle P, et al.: Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in the treatment of symptomatic benign prostatic hyperplasia: the prospective European doxazosin and combination therapy (PREDICT) trial. Urology 2003, 61:119–126.CrossRefPubMed
28.
Lepor H, Williford WO, Barry MJ, et al.: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia: Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996, 335:533–539.CrossRefPubMed
29.
McConnell JD, Roehrborn CG, Bautista OM, et al.: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003, 349:2387–2398.CrossRefPubMed
30.
Van Kerrebroeck P, Kreder K, Jonas U, et al.: Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology 2001, 57:414–421.CrossRefPubMed
31.
Roehrborn CG, Boyle P, Nickel JC, et al.; ARIA3001 ARIA3002 and ARIA3003 Study Investigators: Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002, 60:434–441.CrossRefPubMed
32.
Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al.: Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized controlled trial. J Urol 2003, 169:2253–2256.CrossRefPubMed
33.
Lee KS, Choo MS, Kim DY, et al.: Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 2005, 174:1334–1338.CrossRefPubMed
34.
Kaplan SA, Roehrborn CG, Rovner ES, et al.: Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006, 296:2319–2328CrossRefPubMed
35.
Kaplan SA, Roehrborn CG, Chancellor M, et al.: Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the international prostate symptom score. BJU International 2008, 102:1133–1139.CrossRefPubMed
36.
Rovner ES, Kreder K, Sussman DO, et al.: Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol 2008, 180:1034–1041.CrossRefPubMed
37.
Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M and Guan Z: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol 2009, 56:534–541.CrossRefPubMed
38.
MacDiarmid SA, Peters KM, Chen A, et al.: Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized double-blind placebo-controlled study. Mayo Clin Proc 2008, 83:1002–1010.CrossRefPubMed
39.
Roehrborn CG, Kaplan SA, Kraus SR, et al.: Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS including OAB. Urology 2008, 72:1061–1067.CrossRefPubMed
40.
Roehrborn CG, Kaplan SA, Jones JS, et al.: Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effect of prostate size. Eur Urol 2009, 55:472–479.CrossRefPubMed
41.
• Chung DE, Te AE, Staskin DR, Kaplan SA: Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams. Urology 2010, 75:1144–1148. This is a good study examining efficacy of combination therapy of an antimuscarinic agent with a 5-α-reductase inhibitor. CrossRefPubMed
42.
Cameron A, Clemens J, Latini J, McGuire E, . Combination Drug Therapy Improves Compliance of the Neurogenic Bladder. J Urol 2009;182(3):1062–7.CrossRefPubMed
43.
Amend B, Hennenlotter J, Schafer T, Horstmann M, Stenzl A, Sievert K. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol 2008;53(5):1021–8.CrossRefPubMed
44.
Abrams PH, Farrar DJ, Turner-Warwick RT, et al.: The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients. J Urol 1979, 121:640–642.PubMed
45.
de Nunzio C, Franco G, Rocchegian A, et al.: The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction. J Urol 2003, 169:535–539.CrossRefPubMed
46.
Donovan JL, Peters TJ, Neal DE, et al.: A randomized trial comparing transurethral resection of the prostate, laser therapy and conservative treatment of men with symptoms associated with benign prostatic enlargement: The CLasP study. J Urol 2000, 164:65–70.CrossRefPubMed
47.
Housami F, Abrams P: Persistent detrusor overactivity after transurethral resection of the prostate. Curr Urol Rep 2008, 9:284–290.CrossRefPubMed
Metadata
Title
Overactive Bladder and Outlet Obstruction in Men
Authors
Doreen E. Chung
Jaspreet S. Sandhu
Publication date
01-02-2011
Publisher
Current Science Inc.
Published in
Current Urology Reports / Issue 1/2011
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-010-0157-x

Other articles of this Issue 1/2011

Current Urology Reports 1/2011 Go to the issue

ReviewPaper

Stem Cells for the Treatment of Urinary Incontinence

ReviewPaper

New Advances in Benign Prostatic Hyperplasia: Laser Therapy

ReviewPaper

Impact of Genetics on the Diagnosis and Treatment of Renal Cancer

ReviewPaper

Surgical Management of Renal Cystic Disease

ReviewPaper

Emerging Concepts for Pelvic Organ Prolapse Surgery: What is Cure?

ReviewPaper

Metabolic Profiling for the Detection of Bladder Cancer